Brelgometon (INN; developmental code name ATH-1105) is a positive modulator of hepatocyte growth factor (HGF)–c-MET signaling which is under development for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.